コンテンツへスキップ
Merck

HCKP1-11K-PX17

MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Premixed 17-plex Panel 1 - 免疫学-腫瘍学マルチプレックスアッセイ

Premixed Human Immuno-Oncology Checkpoint Protein 17-Plex Panel 1

別名:

17-Plex 免疫腫瘍学キット, ヒトチェックポイントタンパク質パネル, 免疫腫瘍学 17-Plex パネル

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

NACRES:
NA.77
UNSPSC Code:
12161503
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします


製品名

MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Premixed 17-plex Panel 1 - 免疫学-腫瘍学マルチプレックスアッセイ,

description

Premixed Human Immuno-Oncology Checkpoint Protein 17-Plex Panel 1

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

plasma
cell culture supernatant(s)

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 17 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2)

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • Simultaneous Immune Checkpoint Analysis: Quantify 17 co-stimulatory (CD28, ICOS) and co-inhibitory (PD-1, CTLA-4) proteins in a single assay using a multiplex immuno-oncology panel, enabling efficient study of immune activation pathways and cancer immunotherapy mechanisms.
  • Premixed Bead Convenience: Ready-to-use magnetic beads eliminate manual preparation, reducing setup time and ensuring consistent batch-to-batch performance.
  • Therapeutic Relevance: Directly aligns with immune checkpoint inhibitor research (e.g., anti-PD-1/PD-L1 therapies) to advance oncology outcomes.
  • Standardized Protocols: Pre-optimized dilution guidelines (1:2 for serum/plasma) minimize experimental variability.

Legal Information

Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.



signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

保管分類

10 - Combustible liquids

wgk

WGK 3


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

キットコンポーネントの情報を参照してください

pdsc

キットコンポーネントの情報を参照してください

prtr

キットコンポーネントの情報を参照してください

fsl

キットコンポーネントの情報を参照してください

ishl_indicated

キットコンポーネントの情報を参照してください

ishl_notified

キットコンポーネントの情報を参照してください

cart

キットコンポーネントの情報を参照してください

jan



試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする